Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Torsten Haferlach

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Concepts & Ideas

Gene Expression Profiling

Physiology

Mutation

Devices

Oligonucleotide Array Sequence Analysis

Chemicals & Drugs

Anatomy

Chromosomes, Human, Pair 8

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
87
Hiddemann, Wolfgang
87
Schoch, Claudia
63
Schnittger, Susanne
59
Kern, Wolfgang
34
Löffler, Helmut
27
Schnittger, Susanne
24
Haferlach, Claudia
24
Kern, Wolfgang
24
Büchner, Thomas
22
Kohlmann, Alexander
22
Ludwig, Wolf-Dieter
20
Bacher, Ulrike
19
Heinecke, Achim
19
Sauerland, Maria Cristina
17
Fonatsch, Christa

Sign-in to see all Coauthors

Publications

TOP 3
Bacher Ulrike; Schnittger Susanne; Kern Wolfgang; Weiss Tamara; Haferlach Torsten; Haferlach Claudia
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Kern Wolfgang; Dicker Frank; Schnittger Susanne; Haferlach Claudia; Haferlach Torsten
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
Bacher Ulrike; Haferlach Torsten; Kern Wolfgang; Weiss Tamara; Schnittger Susanne; Haferlach Claudia
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Torsten Haferlach (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Bacher Ulrike; Schnittger Susanne; Kern Wolfgang; Weiss Tamara; Haferlach Torsten; Haferlach Claudia
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Annals of hematology 2009;88(12):1207-13.
2009: Kern Wolfgang; Dicker Frank; Schnittger Susanne; Haferlach Claudia; Haferlach Torsten
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
Cytometry. Part B, Clinical cytometry 2009;76(6):385-93.
2009: Bacher Ulrike; Haferlach Torsten; Kern Wolfgang; Weiss Tamara; Schnittger Susanne; Haferlach Claudia
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
Cancer 2009;115(19):4524-32.
2009: Haferlach Claudia; Mecucci Cristina; Schnittger Susanne; Kohlmann Alexander; Mancini Marco; Cuneo Antonio; Testoni Nicoletta; Rege-Cambrin Giovanna; Santucci Antonella; Vignetti Marco; Fazi Paola; Martelli Maria Paola; Haferlach Torsten; Falini Brunangelo
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
Blood 2009;114(14):3024-32.
2009: Munker Reinhold; Nordberg Mary Lowery; Veillon Diana; Williams B Jill; Roggero Anthony; Kern Wolfgang; Dicker Frank; Haferlach Torsten
Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).
Leukemia research 2009;33(10):1405-8.
2009: Schnittger Susanne; Bacher Ulrike; Kern Wolfgang; Tschulik Claudia; Weiss Tamara; Haferlach Claudia; Haferlach Torsten
RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
British journal of haematology 2009;146(6):665-8.
2009: Schnittger Susanne; Kern Wolfgang; Tschulik Claudia; Weiss Tamara; Dicker Frank; Falini Brunangelo; Haferlach Claudia; Haferlach Torsten
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
Blood 2009;114(11):2220-31.
2009: Mills Ken I; Kohlmann Alexander; Williams P Mickey; Wieczorek Lothar; Liu Wei-min; Li Rachel; Wei Wen; Bowen David T; Loeffler Helmut; Hernandez Jesus M; Hofmann Wolf-Karsten; Haferlach Torsten
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.
Blood 2009;114(5):1063-72.
2009: Valent Peter; Hofmann Wolf-Karsten; Büsche Guntram; Sotlar Karl; Horny Hans-Peter; Haase Detlef; Haferlach Torsten; Kern Wolfgang; Bettelheim Peter; Baumgartner Christian; Sperr Wolfgang R; Nösslinger Thomas; Wimazal Friedrich; Giagounidis Aristoteles A; Lübbert Michael; Krieger Otto; Kolb Hans-Jochem; Stauder Reinhard; Pfeilstöcker Michael; Gattermann Norbert; Fonatsch Christa; Aul Carlo; Germing Ulrich
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.
Annals of hematology 2009;88(7):607-11.
2009: Bacher Ulrike; Kohlmann Alexander; Haferlach Claudia; Haferlach Torsten
Gene expression profiling in acute myeloid leukaemia (AML).
Best practice & research. Clinical haematology 2009;22(2):169-80.
2009: Bacher Ulrike; Kohlmann Alexander; Haferlach Torsten
Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
British journal of haematology 2009;145(5):555-68.
2009: Zatkova Andrea; Merk Sylvia; Wendehack Melanie; Bilban Martin; Muzik Eva Maria; Muradyan Artur; Haferlach Claudia; Haferlach Torsten; Wimmer Katharina; Fonatsch Christa; Ullmann Reinhard
AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes.
Genes, chromosomes & cancer 2009;48(6):510-20.
2009: Bacher Ulrike; Kohlmann Alexander; Haferlach Torsten
Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies.
Briefings in functional genomics & proteomics 2009;8(3):184-93.
2009: Haferlach T; Kohlmann A; Klein H-U; Ruckert C; Dugas M; Williams P M; Kern W; Schnittger S; Bacher U; Löffler H; Haferlach C
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(5):934-43.
2009: Bojko Peter; Abenhardt Wolfgang; Schnittger Susanne; Haferlach Torsten
Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
Onkologie 2009;32(4):191-5.
2009: Breitenbuecher Frank; Schnittger Susanne; Grundler Rebekka; Markova Boyka; Carius Birgit; Brecht Alexandra; Duyster Justus; Haferlach Torsten; Huber Christoph; Fischer Thomas
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.
Blood 2009;113(17):4074-7.
2009: Schnittger Susanne; Bacher Ulrike; Haferlach Claudia; Geer Thomas; Müller Peter; Mittermüller Johann; Petrides Petro; Schlag Rudolf; Sandner Reiner; Selbach Johannes; Slawik Hans Rainer; Tessen Hans Werner; Wehmeyer Jürgen; Kern Wolfgang; Haferlach Torsten
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Haematologica 2009;94(3):414-8.
2009: Akagi Tadayuki; Ogawa Seishi; Dugas Martin; Kawamata Norihiko; Yamamoto Go; Nannya Yasuhito; Sanada Masashi; Miller Carl W; Yung Amanda; Schnittger Susanne; Haferlach Torsten; Haferlach Claudia; Koeffler H Phillip
Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.
Haematologica 2009;94(2):213-23.
2009: Büchner Thomas; Berdel Wolfgang E; Haferlach Claudia; Haferlach Torsten; Schnittger Susanne; Müller-Tidow Carsten; Braess Jan; Spiekermann Karsten; Kienast Joachim; Staib Peter; Grüneisen Andreas; Kern Wolfgang; Reichle Albrecht; Maschmeyer Georg; Aul Carlo; Lengfelder Eva; Sauerland Maria-Cristina; Heinecke Achim; Wörmann Bernhard; Hiddemann Wolfgang
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):61-9.
2009: Schnittger Susanne; Bacher Ulrike; Haferlach Claudia; Beelen Dietrich; Bojko Peter; Bürkle Dieter; Dengler Robert; Distelrath Andrea; Eckart Michael; Eckert Robert; Fries Stefan; Knoblich Jan; Köchling Georg; Laubenstein Hans-Peter; Petrides Petro; Planker Manfred; Pihusch Rudolf; Weide Rudolf; Kern Wolfgang; Haferlach Torsten
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Haematologica 2009;94(1):141-4.
2009: Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(1):117-24.
2009: Bacher Ulrike; Schnittger Susanne; Haferlach Claudia; Haferlach Torsten
Molecular diagnostics in acute leukemias.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(11):1333-41.
2009: Haferlach Torsten; Bacher Ulrike; Kohlmann Alexander; Haferlach Claudia
Discussion of the applicability of microarrays: profiling of leukemias.
Methods in molecular biology (Clifton, N.J.) 2009;509():15-33.
2008: Berg Tobias; Fliegauf Manfred; Burger Jan; Staege Martin S; Liu Shaohua; Martinez Natalia; Heidenreich Olaf; Burdach Stefan; Haferlach Torsten; Werner Milton H; Lübbert Michael
Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.
Haematologica 2008;93(11):1728-33.
2008: Kohlmann Alexander; Haschke-Becher Elisabeth; Wimmer Barbara; Huber-Wechselberger Ariana; Meyer-Monard Sandrine; Huxol Heike; Siegler Uwe; Rossier Michel; Matthes Thomas; Rebsamen Michela; Chiappe Alberto; Diemand Adeline; Rauhut Sonja; Johnson Andrea; Liu Wei-Min; Williams P Mickey; Wieczorek Lothar; Haferlach Torsten
Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study.
Clinical chemistry 2008;54(10):1705-15.
2008: Kohlmann Alexander; Kipps Thomas J; Rassenti Laura Z; Downing James R; Shurtleff Sheila A; Mills Ken I; Gilkes Amanda F; Hofmann Wolf-Karsten; Basso Giuseppe; Dell'orto Marta Campo; Foà Robin; Chiaretti Sabina; De Vos John; Rauhut Sonja; Papenhausen Peter R; Hernández Jesus M; Lumbreras Eva; Yeoh Allen E; Koay Evelyn S; Li Rachel; Liu Wei-Min; Williams Paul M; Wieczorek Lothar; Haferlach Torsten
An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase.
British journal of haematology 2008;142(5):802-7.
2008: Liso Arcangelo; Castiglione Filippo; Cappuccio Antonio; Stracci Fabrizio; Schlenk Richard F; Amadori Sergio; Thiede Christian; Schnittger Susanne; Valk Peter J M; Döhner Konstanze; Martelli Massimo F; Schaich Markus; Krauter Jürgen; Ganser Arnold; Martelli Maria P; Bolli Niccolò; Löwenberg Bob; Haferlach Torsten; Ehninger Gerhard; Mandelli Franco; Döhner Hartmut; Michor Franziska; Falini Brunangelo
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
Haematologica 2008;93(8):1219-26.
2008: Bacher U; Zander A R; Haferlach T; Schnittger S; Fehse B; Kröger N
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
Bone marrow transplantation 2008;42(3):145-57.
2008: Haferlach C; Dicker F; Herholz H; Schnittger S; Kern W; Haferlach T
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(8):1539-41.
2008: Falini Brunangelo; Martelli Maria Paola; Mecucci Cristina; Liso Arcangelo; Bolli Niccolò; Bigerna Barbara; Pucciarini Alessandra; Pileri Stefano; Meloni Giovanna; Martelli Massimo F; Haferlach Torsten; Schnittger Susanne
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Haematologica 2008;93(5):775-9.
2008: Garzon Ramiro; Garofalo Michela; Martelli Maria Paola; Briesewitz Roger; Wang Lisheng; Fernandez-Cymering Cecilia; Volinia Stefano; Liu Chang-Gong; Schnittger Susanne; Haferlach Torsten; Liso Arcangelo; Diverio Daniela; Mancini Marco; Meloni Giovanna; Foa Robin; Martelli Massimo F; Mecucci Cristina; Croce Carlo M; Falini Brunangelo
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(10):3945-50.
2008: Falini Brunangelo; Mecucci Cristina; Saglio Giuseppe; Lo Coco Francesco; Diverio Daniela; Brown Patrick; Pane Fabrizio; Mancini Marco; Martelli Maria Paola; Pileri Stefano; Haferlach Torsten; Haferlach Claudia; Schnittger Susanne
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
Haematologica 2008;93(3):439-42.
2008: Bacher Ulrike; Haferlach Claudia; Kern Wolfgang; Haferlach Torsten; Schnittger Susanne
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
Blood 2008;111(5):2527-37.
2008: Schnittger S; Bacher U; Haferlach C; Dengler R; Kröber A; Kern W; Haferlach T
Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(2):453-5.
2008: Kern Wolfgang; Haferlach Claudia; Haferlach Torsten; Schnittger Susanne
Monitoring of minimal residual disease in acute myeloid leukemia.
Cancer 2008;112(1):4-16.
2008: Haferlach Torsten; Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Haferlach Claudia
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
Annals of hematology 2008;87(1):1-10.
2007: Haferlach C; Dicker F; Schnittger S; Kern W; Haferlach T
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(12):2442-51.
2007: Weisser Martin; Haferlach Claudia; Haferlach Torsten; Schnittger Susanne
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.
Leukemia & lymphoma 2007;48(11):2145-51.
2007: Haferlach Torsten; Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Haferlach Claudia
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]
Medizinische Klinik (Munich, Germany : 1983) 2007;102(9):770-7.
2007: Weisser Martin; Haferlach Claudia; Haferlach Torsten; Schnittger Susanne
Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.
Cancer genetics and cytogenetics 2007;177(1):64-9.
2007: Tschoep Katharina; Kohlmann Alexander; Schlemmer Marcus; Haferlach Torsten; Issels Rolf-Dieter
Gene expression profiling in sarcomas.
Critical reviews in oncology/hematology 2007;63(2):111-24.
2007: Dicker Frank; Haferlach Claudia; Kern Wolfgang; Haferlach Torsten; Schnittger Susanne
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.
Blood 2007;110(4):1308-16.
2007: Schnittger S; Bacher U; Kern W; Haferlach T; Haferlach C
JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(8):1843-5.
2007: Bacher Ulrike; Haferlach Torsten; Kern Wolfgang; Haferlach Claudia; Schnittger Susanne
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Haematologica 2007;92(6):744-52.
2007: Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller M C; Beneke H; Müller L; Del Valle F; Aulitzky W E; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker S J; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross N C P; Reiter A
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(6):1183-8.
2007: Valent Peter; Horny Hans-Peter; Bennett John M; Fonatsch Christa; Germing Ulrich; Greenberg Peter; Haferlach Torsten; Haase Detlef; Kolb Hans-Jochen; Krieger Otto; Loken Michael; van de Loosdrecht Arjan; Ogata Kiyoyuki; Orfao Alberto; Pfeilstöcker Michael; Rüter Björn; Sperr Wolfgang R; Stauder Reinhard; Wells Denise A
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.
Leukemia research 2007;31(6):727-36.
2007: Bacher Ulrike; Haferlach Torsten; Kern Wolfgang; Harich Hans-Detlev; Schnittger Susanne; Haferlach Claudia
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Cancer genetics and cytogenetics 2007;175(1):52-6.
2007: Haferlach Torsten; Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Haferlach Claudia
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.
Annals of hematology 2007;86(5):311-27.
2007: Herholz Hannes; Kern Wolfgang; Schnittger Susanne; Haferlach Torsten; Dicker Frank; Haferlach Claudia
Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 2007;174(1):57-60.
2007: Schnittger S; Bacher U; Haferlach C; Kern W; Haferlach T
Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(4):725-31.
2007: Haferlach Torsten; Bacher Ulrike; Haferlach Claudia; Kern Wolfgang; Schnittger Susanne
Insight into the molecular pathogenesis of myeloid malignancies.
Current opinion in hematology 2007;14(2):90-7.
2007: Haferlach T; Kohlmann A; Bacher U; Schnittger S; Haferlach C; Kern W
Gene expression profiling for the diagnosis of acute leukaemia.
British journal of cancer 2007;96(4):535-40.
2007: Schnittger S; Bacher U; Kern W; Haferlach C; Haferlach T
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(1):183-4.
2006: Weisser Martin; Kern Wolfgang; Schoch Claudia; Tschulik Claudia; Hiddemann Wolfgang; Haferlach Torsten; Schnittger Susanne
Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
Leukemia & lymphoma 2006;47(12):2645-7.
2006: Schoch Claudia; Kohlmann Alexander; Dugas Martin; Kern Wolfgang; Schnittger Susanne; Haferlach Torsten
Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups.
Genes, chromosomes & cancer 2006;45(12):1164-8.
2006: Haferlach Torsten; Bacher Ulrike; Kohlmann Alexander; Schnittger Susanne; Kern Wolfgang; Haferlach Claudia
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]
Medizinische Klinik (Munich, Germany : 1983) 2006;101(11):908-14.
2006: Kern Wolfgang; Kohlmann Alexander; Schoch Claudia; Schnittger Susanne; Haferlach Torsten
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.
Cancer 2006;107(10):2401-7.
2006: Chapiro Elise; Delabesse Eric; Asnafi Vahid; Millien Corinne; Davi Frederic; Nugent Elizabeth; Beldjord Kheira; Haferlach Torsten; Grimwade David; Macintyre Elizabeth A
Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17).
Blood 2006;108(10):3484-93.
2006: Dicker Frank; Schnittger Susanne; Haferlach Torsten; Kern Wolfgang; Schoch Claudia
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression.
Blood 2006;108(9):3152-60.
2006: Saussele S; Adam K; Hochhaus A; Béné M C; Büchner T; Burnett A; Finazzi G; Fonatsch C; Gluckman E; Gökbuget N; Grimwade D J; Haferlach T; Hallek M; Hasford J; Hoelzer D; Ljungman P; Niederwieser D; Serve H; Simonsson B; de Witte T J; Hehlmann R;
[Clinical research at the European LeukemiaNet]
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2423-6.
2006: Walz Christoph; Curtis Claire; Schnittger Susanne; Schultheis Beate; Metzgeroth Georgia; Schoch Claudia; Lengfelder Eva; Erben Philipp; Müller Martin C; Haferlach Torsten; Hochhaus Andreas; Hehlmann Rüdiger; Cross Nicholas C P; Reiter Andreas
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Genes, chromosomes & cancer 2006;45(10):950-6.
2006: Kuchenbauer F; Schnittger S; Look T; Gilliland G; Tenen D; Haferlach T; Hiddemann W; Buske C; Schoch C
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
British journal of haematology 2006;134(6):616-9.
2006: Bacher Ulrike; Schnittger Susanne; Kern Wolfgang; Trenn Guido; Weisser Martin; Haferlach Torsten; Schoch Claudia
Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Cancer genetics and cytogenetics 2006;168(2):172-4.
2006: Bacher Ulrike; Reiter Andreas; Haferlach Torsten; Mueller Lothar; Schnittger Susanne; Kern Wolfgang; Schoch Claudia
A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.
Haematologica 2006;91(6):817-20.
2006: Büchner Thomas; Berdel Wolfgang E; Schoch Claudia; Haferlach Torsten; Serve Hubert L; Kienast Joachim; Schnittger Susanne; Kern Wolfgang; Tchinda Joelle; Reichle Albrecht; Lengfelder Eva; Staib Peter; Ludwig Wolf-Dieter; Aul Carlo; Eimermacher Hartmut; Balleisen Leopold; Sauerland Maria-Cristina; Heinecke Achim; Wörmann Bernhard; Hiddemann Wolfgang
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2480-9.
2006: Falini Brunangelo; Bolli Niccolò; Shan Jing; Martelli Maria Paola; Liso Arcangelo; Pucciarini Alessandra; Bigerna Barbara; Pasqualucci Laura; Mannucci Roberta; Rosati Roberto; Gorello Paolo; Diverio Daniela; Roti Giovanni; Tiacci Enrico; Cazzaniga Giovanni; Biondi Andrea; Schnittger Suzanne; Haferlach Torsten; Hiddemann Wolfgang; Martelli Massimo F; Gu Wei; Mecucci Cristina; Nicoletti Ildo
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.
Blood 2006;107(11):4514-23.
2006: Bacher Ulrike; Haferlach Torsten; Schoch Claudia; Kern Wolfgang; Schnittger Susanne
Implications of NRAS mutations in AML: a study of 2502 patients.
Blood 2006;107(10):3847-53.
2006: Schnittger Susanne; Kohl Tobias M; Leopold Nina; Schoch Claudia; Wichmann H-Erich; Kern Wolfgang; Lohse Peter; Hiddemann Wolfgang; Haferlach Torsten; Spiekermann Karsten
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias.
Genes, chromosomes & cancer 2006;45(4):332-7.
2006: Schnittger Susanne; Kohl Tobias M; Haferlach Torsten; Kern Wolfgang; Hiddemann Wolfgang; Spiekermann Karsten; Schoch Claudia
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
Blood 2006;107(5):1791-9.
2006: Bacher Ulrike; Kern Wolfgang; Schoch Claudia; Schnittger Susanne; Hiddemann Wolfgang; Haferlach Torsten
Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
Cancer 2006;106(4):839-47.
2006: Mueller Susanne; Holdenrieder Stefan; Stieber Petra; Haferlach Torsten; Schalhorn Andreas; Braess Jan; Nagel Dorothea; Seidel Dietrich
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.
BMC cancer 2006;6():143.
2006: Kohlmann Alexander; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten
Classification of AML by DNA-oligonucleotide microarrays.
Methods in molecular medicine 2006;125():213-40.
2005: Kuchenbauer Florian; Kern Wolfgang; Schoch Claudia; Kohlmann Alexander; Hiddemann Wolfgang; Haferlach Torsten; Schnittger Susanne
Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Haematologica 2005;90(12):1617-25.
2005: Schnittger Susanne; Schoch Claudia; Kern Wolfgang; Mecucci Cristina; Tschulik Claudia; Martelli Massimo F; Haferlach Torsten; Hiddemann Wolfgang; Falini Brunangelo
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Blood 2005;106(12):3733-9.
2005: Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Hiddemann Wolfgang; Haferlach Torsten; Schoch Claudia
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
Haematologica 2005;90(11):1502-10.
2005: Büchner Thomas; Berdel Wolfgang E; Wörmann Bernhard; Schoch Claudia; Haferlach Torsten; Schnittger Susanne; Kern Wolfgang; Aul Carlo; Lengfelder Eva; Schumacher Andrea; Reichle Albrecht; Staib Peter; Balleisen Leopold; Eimermacher Hartmut; Grüneisen Andreas; Rasche Herbert; Sauerland Maria Cristina; Heinecke Achim; Mesters Rolf M; Serve Hubert L; Kienast Joachim; Hiddemann Wolfgang
Treatment of older patients with AML.
Critical reviews in oncology/hematology 2005;56(2):247-59.
2005: Haferlach Torsten; Kern Wolfgang; Schnittger Susanne; Schoch Claudia
Modern diagnostics in acute leukemias.
Critical reviews in oncology/hematology 2005;56(2):223-34.
2005: Kern Wolfgang; Schoch Claudia; Haferlach Torsten; Schnittger Susanne
Monitoring of minimal residual disease in acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):283-309.
2005: Hiddemann W; Spiekermann K; Buske C; Feuring-Buske M; Braess J; Haferlach T; Schoch C; Kern W; Schnittger S; Berdel W; Wörmann B; Heinecke A; Sauerland C; Büchner Th;
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):235-45.
2005: Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Hiddemann Wolfgang; Schoch Claudia; Haferlach Torsten
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.
Annals of hematology 2005;84(12):785-91.
2005: Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(8):1416-23.
2005: Haferlach Torsten; Kohlmann Alexander; Schnittger Susanne; Dugas Martin; Hiddemann Wolfgang; Kern Wolfgang; Schoch Claudia
Global approach to the diagnosis of leukemia using gene expression profiling.
Blood 2005;106(4):1189-98.
2005: Dicker Frank; Rauhut Sonja; Kohlmann Alexander; Kern Wolfgang; Schoch Claudia; Haferlach Torsten; Schnittger Susanne
Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
Journal of the National Cancer Institute 2005;97(14):1092-3; author reply 1093-5.
2005: Kuchenbauer Florian; Schoch Claudia; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten; Schnittger Susanne
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.
British journal of haematology 2005;130(2):196-202.
2005: Weisser Martin; Kern Wolfgang; Schoch Claudia; Hiddemann Wolfgang; Haferlach Torsten; Schnittger Susanne
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.
Haematologica 2005;90(7):881-9.
2005: Bacher Ulrike; Haferlach Torsten; Schoch Claudia
Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.
Cancer genetics and cytogenetics 2005;160(2):179-83.
2005: Schoch C; Kohlmann A; Dugas M; Kern W; Hiddemann W; Schnittger S; Haferlach T
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(7):1224-8.
2005: Schoch Claudia; Kern Wolfgang; Kohlmann Alexander; Hiddemann Wolfgang; Schnittger Susanne; Haferlach Torsten
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.
Genes, chromosomes & cancer 2005;43(3):227-38.
2005: Kern Wolfgang; Kohlmann Alexander; Schnittger Susanne; Schoch Claudia; Haferlach Torsten
Role of gene expression profiling for diagnosing acute leukemias.
Reviews in clinical and experimental hematology 2005;9(1):E1.
2005: Kohlmann A; Schoch C; Dugas M; Schnittger S; Hiddemann W; Kern W; Haferlach T
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(6):953-64.
2005: Haferlach Torsten; Kohlmann Alexander; Schnittger Susanne; Dugas Martin; Hiddemann Wolfgang; Kern Wolfgang; Schoch Claudia
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes.
Genes, chromosomes & cancer 2005;43(2):113-27.
2005: Herzog Gerhard; Lu-Hesselmann Juxian; Zimmermann Yvonne; Haferlach Torsten; Hiddemann Wolfgang; Dreyling Martin
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events.
Haematologica 2005;90(5):693-5.
2005: Bacher Ulrike; Schnittger Susanne; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten; Schoch Claudia
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
Haematologica 2005;90(4):558-9.
2005: Bacher Ulrike; Haferlach Torsten; Kern Wolfgang; Hiddemann Wolfgang; Schnittger Susanne; Schoch Claudia
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Annals of hematology 2005;84(4):250-7.
2005: Kern Wolfgang; Haferlach Torsten; Schnittger Susanne; Schoch Claudia
Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia.
Archives of pathology & laboratory medicine 2005;129(3):410-1.
2005: Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Hiddemann Wolfgang; Schoch Claudia; Haferlach Torsten
Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia.
Leukemia & lymphoma 2005;46(3):357-66.
2005: Kohlmann Alexander; Schoch Claudia; Dugas Martin; Rauhut Sonja; Weninger Felix; Schnittger Susanne; Kern Wolfgang; Haferlach Torsten
Pattern robustness of diagnostic gene expression signatures in leukemia.
Genes, chromosomes & cancer 2005;42(3):299-307.
2005: Kern W; Diem H; Haferlach T
[Immunophenotyping in modern leukemia diagnosis]
Deutsche medizinische Wochenschrift (1946) 2005;130(5):215-9.
2005: Bacher Ulrike; Haferlach Torsten; Hiddemann Wolfgang; Schnittger Susanne; Kern Wolfgang; Schoch Claudia
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.
Cancer genetics and cytogenetics 2005;157(1):53-61.
2005: Neben Kai; Schnittger Susanne; Brors Benedikt; Tews Björn; Kokocinski Felix; Haferlach Torsten; Müller Jasmin; Hahn Meinhard; Hiddemann Wolfgang; Eils Roland; Lichter Peter; Schoch Claudia
Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Oncogene 2005;24(9):1580-8.
2005: Kern Wolfgang; Haferlach Torsten
[Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis]
Medizinische Klinik (Munich, Germany : 1983) 2005;100(1):54-9.
2005: Buechner Thomas; Berdel Wolfgang E; Schoch Claudia; Haferlach Torsten; Serve Hubert L; Schnittger Susanne; Kern Wolfgang; Tchinda Joelle; Reichle Albrecht; Staib Peter; Ludwig Wolf-Dieter; Aul Carlo; Sauerland Maria-Cristina; Heinecke Achim; Woermann Bernhard; Hiddemann Wolfgang;
Treatment of AML in biological subgroups.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():281-85.
2004: Lenz Georg; Dreyling Martin; Schiegnitz Eva; Haferlach Torsten; Hasford Joerg; Unterhalt Michael; Hiddemann Wolfgang
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(24):4926-33.
2004: Klaus Mirjam; Haferlach Torsten; Schnittger Susanne; Kern Wolfgang; Hiddemann Wolfgang; Schoch Claudia
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Cancer genetics and cytogenetics 2004;155(1):47-56.
2004: Voskova Daniela; Schoch Claudia; Schnittger Susanne; Hiddemann Wolfgang; Haferlach Torsten; Kern Wolfgang
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Cytometry. Part B, Clinical cytometry 2004;62(1):25-38.
2004: Kern Wolfgang; Voskova Daniela; Schoch Claudia; Hiddemann Wolfgang; Schnittger Susanne; Haferlach Torsten
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Blood 2004;104(10):3078-85.
2004: Schoch Claudia; Kern Wolfgang; Schnittger Susanne; Büchner Thomas; Hiddemann Wolfgang; Haferlach Torsten
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Haematologica 2004;89(9):1082-90.
2004: Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(9):1476-81.
2004: Haferlach Torsten
[Molecular classification in leukemias using gene expression profiling]
Medizinische Klinik (Munich, Germany : 1983) 2004;99(8):464-6.
2004: Kern Wolfgang; Haferlach Torsten; Schnittger Susanne; Hiddemann Wolfgang; Schoch Claudia
Prognosis in therapy-related acute myeloid leukemia and impact of karyotype.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2510-1.
2004: Bacher U; Kern W; Schoch C; Hiddemann W; Haferlach T
Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH).
Annals of hematology 2004;83(6):349-55.
2004: Christodoulou J; Schoch C; Schnittger S; Haferlach T
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).
Annals of hematology 2004;83(6):386-9.
2004: Kern Wolfgang; Voskova Daniela; Schoch Claudia; Schnittger Susanne; Hiddemann Wolfgang; Haferlach Torsten
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Haematologica 2004;89(5):528-40.
2004: Grimwade David; Haferlach Torsten
Gene-expression profiling in acute myeloid leukemia.
The New England journal of medicine 2004;350(16):1676-8.
2004: Haferlach Torsten; Kern Wolfgang; Schoch Claudia; Schnittger Susanne; Sauerland Maria Cristina; Heinecke Achim; Büchner Thomas; Hiddemann Wolfgang;
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haematologica 2004;89(4):408-18.
2004: Glasmacher Axel; Goldschmidt Hartmut; Mezger Jörg; Haferlach Torsten; Schmidt-Wolf Ingo G H; Gieseler Frank;
Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial.
Haematologica 2004;89(3):371-3.
2004: Kohlmann A; Schoch C; Schnittger S; Dugas M; Hiddemann W; Kern W; Haferlach T
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(1):63-71.
2004: Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(1):120-5.
2004: Tamm Ingo; Richter Stephan; Scholz Frank; Schmelz Karin; Oltersdorf Doreen; Karawajew Leonid; Schoch Claudia; Haferlach Torsten; Ludwig Wolf-Dieter; Wuchter Christian
XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(6):489-95.
2004: Kern Wolfgang; Voskova Daniela; Schnittger Susanne; Schoch Claudia; Hiddemann Wolfgang; Haferlach Torsten
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(5):410-8.
2004: Kern Wolfgang; Kohlmann Alexander; Schnittger Susanne; Hiddemann Wolfgang; Schoch Claudia; Haferlach Torsten
Gene expression profiling as a diagnostic tool in acute myeloid leukemia.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2004;4(4):225-37.
2004: Schnittger Susanne; Schoch Claudia; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
Acta haematologica 2004;112(1-2):68-78.
2004: Büchner Th; Hiddemann W; Berdel W E; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig W D; Maschmeyer G; Staib P; Balleisen L; Grüneisen A; Aul C; Lengfelder E; Hehlmann R; Kern W; Serve H L; Mesters R M; Eimermacher H; Frickhofen N; Kienast J; Giagounidis A; Sauerland M C; Heinecke A;
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2004: Haferlach T; Kern W; Schnittger S; Schoch C
Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
Annals of hematology 2004;83 Suppl 1():S59-61.
2004: Kern W; Haferlach T; Schoch C; Sauerland M C; Heinecke A; Wörmann B; Berdel W; Büchner Th; Hiddemann W
Risk-adapted therapy of AML: the AMLCG experience.
Annals of hematology 2004;83 Suppl 1():S49-51.
2003: Büchner Thomas; Hiddemann Wolfgang; Berdel Wolfgang E; Wörmann Bernhard; Schoch Claudia; Fonatsch Christa; Löffler Helmut; Haferlach Torsten; Ludwig Wolf-Dieter; Maschmeyer Georg; Staib Peter; Aul Carlo; Gruneisen Andreas; Lengfelder Eva; Frickhofen Norbert; Kern Wolfgang; Serve Hubert L; Mesters Rolf M; Sauerland Maria Cristina; Heinecke Achim;
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4496-504.
2003: Lenz Georg; Golf Alexander; Rüdiger Thomas; Hiddemann Wolfgang; Haferlach Torsten
Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine.
Blood 2003;102(9):3457-8.
2003: Haferlach Torsten; Kohlmann Alexander; Kern Wolfgang; Hiddemann Wolfgang; Schnittger Susanne; Schoch Claudia
Gene expression profiling as a tool for the diagnosis of acute leukemias.
Seminars in hematology 2003;40(4):281-95.
2003: Schnittger Susanne; Weisser Martin; Schoch Claudia; Hiddemann Wolfgang; Haferlach Torsten; Kern Wolfgang
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.
Blood 2003;102(8):2746-55.
2003: Schoch Claudia; Schnittger Susanne; Klaus Mirjam; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
Blood 2003;102(7):2395-402.
2003: Tschoep K; Kohlmann A; Schlemmer M; Haferlach T; Issels R
[Gene expression analysis using DNA microarrays in soft tissue and bone tumors]
Deutsche medizinische Wochenschrift (1946) 2003;128(39):2030-6.
2003: Kern Wolfgang; Kohlmann Alexander; Wuchter Christian; Schnittger Susanne; Schoch Claudia; Mergenthaler Susanne; Ratei Richard; Ludwig Wolf-Dieter; Hiddemann Wolfgang; Haferlach Torsten
Correlation of protein expression and gene expression in acute leukemia.
Cytometry. Part B, Clinical cytometry 2003;55(1):29-36.
2003: Fiegl Michael; Rieger Christina; Braess Jan; Haferlach Torsten; Schnittger Susanne; Schoch Claudia; Hiddemann Wolfgang; Ostermann Helmut
Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acid.
British journal of haematology 2003;122(4):688-9.
2003: Kohlmann Alexander; Schoch Claudia; Schnittger Susanne; Dugas Martin; Hiddemann Wolfgang; Kern Wolfgang; Haferlach Torsten
Molecular characterization of acute leukemias by use of microarray technology.
Genes, chromosomes & cancer 2003;37(4):396-405.
2003: Rangatia Janki; Vangala Rajani K; Singh Sheo M; Peer Zada Abdul A; Elsässer Annika; Kohlmann Alexander; Haferlach Torsten; Tenen Daniel G; Hiddemann Wolfgang; Behre Gerhard
Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction.
Oncogene 2003;22(30):4760-4.
2003: Klaus Mirjam; Schnittger Susanne; Haferlach Torsten; Dreyling Martin; Hiddemann Wolfgang; Schoch Claudia
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement.
Cancer genetics and cytogenetics 2003;144(1):36-43.
2003: Kern Wolfgang; Danhauser-Riedl Susanne; Ratei Richard; Schnittger Susanne; Schoch Claudia; Kolb Hans-Jochem; Ludwig Wolf-Dieter; Hiddemann Wolfgang; Haferlach Torsten
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
Haematologica 2003;88(6):646-53.
2003: Zada Abdul A Peer; Singh Sheo M; Reddy Venkateshwar A; Elsässer Annika; Meisel Alexander; Haferlach Torsten; Tenen Daniel G; Hiddemann Wolfgang; Behre Gerhard
Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation.
Oncogene 2003;22(15):2296-308.
2003: Gehrmann Mathias; Schmetzer Helga; Eissner Günther; Haferlach Torsten; Hiddemann Wolfgang; Multhoff Gabriele
Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells.
Haematologica 2003;88(4):474-6.
2003: Schoch Claudia; Schnittger Susanne; Kern Wolfgang; Dugas Martin; Hiddemann Wolfgang; Haferlach Torsten
Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia.
Haematologica 2003;88(3):351-2.
2003: Haferlach Torsten; Schoch Claudia; Löffler Helmut; Gassmann Winfried; Kern Wolfgang; Schnittger Susanne; Fonatsch Christa; Ludwig Wolf-Dieter; Wuchter Christian; Schlegelberger Brigitte; Staib Peter; Reichle Albrecht; Kubica Uschi; Eimermacher Hartmut; Balleisen Leopold; Grüneisen Andreas; Haase Detlef; Aul Carlo; Karow Jochen; Lengfelder Eva; Wörmann Bernhard; Heinecke Achim; Sauerland Maria Cristina; Büchner Thomas; Hiddemann Wolfgang
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):256-65.
2003: Kern Wolfgang; Haferlach Torsten; Schoch Claudia; Loffler Helmut; Gassmann Winfried; Heinecke Achim; Sauerland Maria Christina; Berdel Wolfgang; Buchner Thomas; Hiddemann Wolfgang
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Blood 2003;101(1):64-70.
2002: Spiekermann Karsten; Bagrintseva Ksenia; Schoch Claudia; Haferlach Torsten; Hiddemann Wolfgang; Schnittger Susanne
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
Blood 2002;100(9):3423-5.
2002: Haferlach T; Schoch C
[Modern techniques in leukemia diagnosis]
Der Internist 2002;43(10):1190, 1193-6, 1199-202.
2002: Kohlmann A; Schoch C; Schnittger S; Kern W; Haferlach T
[Diagnosis of leukemia using microarray technology]
Deutsche medizinische Wochenschrift (1946) 2002;127(42):2216-22.
2002: Kern W; Haferlach T; Schnittger S; Ludwig W D; Hiddemann W; Schoch C
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(10):2084-91.
2002: Schoch Claudia; Haferlach Torsten; Bursch Sabina; Gerstner Daniela; Schnittger Susanne; Dugas Martin; Kern Wolfgang; Löffler Helmut; Hiddemann Wolfgang
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Genes, chromosomes & cancer 2002;35(1):20-9.
2002: Buhmann Raymund; Kurzeder Christian; Rehklau Jutta; Westhaus Doreen; Bursch Sabina; Hiddemann Wolfgang; Haferlach Torsten; Hallek Michael; Schoch Claudia
CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells.
British journal of haematology 2002;118(4):968-75.
2002: Schoch Claudia; Haferlach Torsten
Cytogenetics in acute myeloid leukemia.
Current oncology reports 2002;4(5):390-7.
2002: Haferlach Torsten; Schoch Claudia; Schnittger Susanne; Kern Wolfgang; Löffler Helmut; Hiddemann Wolfgang
Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients.
British journal of haematology 2002;118(2):426-31.
2002: Schoch Claudia; Kohlmann Alexander; Schnittger Susanne; Brors Benedikt; Dugas Martin; Mergenthaler Susanne; Kern Wolfgang; Hiddemann Wolfgang; Eils Roland; Haferlach Torsten
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(15):10008-13.
2002: Schnittger Susanne; Schoch Claudia; Dugas Martin; Kern Wolfgang; Staib Peter; Wuchter Christian; Löffler Helmut; Sauerland Cristina Maria; Serve Hubert; Büchner Thomas; Haferlach Torsten; Hiddemann Wolfgang
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Blood 2002;100(1):59-66.
2002: Salih Helmut R; Starling Gary C; Brandl Stephan F; Pelka-Fleischer Renate; Haferlach Torsten; Hiddemann Wolfgang; Kiener Peter A; Nuessler Volkmar
Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.
British journal of haematology 2002;117(1):76-85.
2002: Büchner Thomas; Hiddemann Wolfgang; Berdel Wolfgang; Wörmann Bernhard; Schoch Claudia; Löffler Helmut; Haferlach Torsten; Schumacher Andrea; Staib Peter; Balleisen Leopold; Grüneisen Andreas; Rasche Herbert; Aul Carlo; Heyll Axel; Lengfelder Eva; Ludwig Wolf-Dieter; Maschmeyer Georg; Eimermacher Hartmut; Karow Jochen; Frickhofen Norbert; Hirschmann Wolf-Dietrich; Sauerland Maria-Cristina;
Acute myeloid leukemia: treatment over 60.
Reviews in clinical and experimental hematology 2002;6(1):46-59; discussion 86-7.
2002: Haferlach T; Schoch C
[WHO classification of acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)]
Deutsche medizinische Wochenschrift (1946) 2002;127(9):447-50.
2002: Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(1):53-9.
2002: Dugas Martin; Schoch Claudia; Schnittger Susanne; Kohlmann Alexander; Kern Wolfgang; Haferlach Torsten; Uberla Karl
Impact of integrating clinical and genetic information.
In silico biology 2002;2(3):383-91.
2002: Schoch Claudia; Schnittger Susanne; Kern Wolfgang; Lengfelder Eva; Löffler Helmut; Hiddemann Wolfgang; Haferlach Torsten
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(5):259-63.
2001: Schoch R; Pitako J; Schafhausen P; Jenisch S; Haferlach T; Kneba M; Suttorp M
Semiquantitative reverse transcription polymerase chain reaction analysis for detection of bcr/abl rearrangement using RNA extracts from bone marrow aspirates compared with glass slide smears after 0, 2 and 4 d of storage.
British journal of haematology 2001;115(3):583-7.
2001: Büchner T; Hiddemann W; Berdel W; Wörmann B; Löffler H; Schoch C; Haferlach T; Ludwig W D; Maschmeyer G; Staib P; Andreesen R; Balleisen L; Haase D; Eimermacher H; Aul C; Rasche H; Uhlig J; Grüneisen A; Reis H E; Hartlapp J; Hirschmann W D; Weh H J; Pielken H J; Gassmann W; Sauerland M C; Heinecke A
Remission induction therapy: the more intensive the better?
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S41-4.
2001: Braess J; Jahns-Streubel G; Schoch C; Haase D; Haferlach T; Fiegl M; Voss S; Kern W; Schleyer E; Hiddemann W
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
British journal of haematology 2001;113(4):975-82.
2001: Schoch C; Bursch S; Kern W; Schnittger S; Hiddemann W; Haferlach T
Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia.
Cancer genetics and cytogenetics 2001;127(1):85-8.
2001: Wuchter C; Ratei R; Spahn G; Schoch C; Harbott J; Schnittger S; Haferlach T; Creutzig U; Sperling C; Karawajew L; Ludwig W D
Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping.
Haematologica 2001;86(2):154-61.
2001: Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland M C; Heinecke A; Büchner T; Hiddemann W;
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
British journal of haematology 2001;112(1):118-26.
2001: Haferlach T
Quantitative reverse transcriptase-polymerase chain reaction in AML with t(8;21)(q22;q22).
Leukemia research 2001;25(1):55-56.
2000: Büchner T; Hiddemann W; Wörmann B; Löffler H; Ludwig W D; Schoch C; Haferlach T; Maschmeyer G; Staib P; Aul C; Heyll G A; Grüneisen A; Rasche H; Eimermacher J H; Balleisen L; Pielken H J; Reis H E; Griesinger F; Reichle A; Sauerland M C; Heinecke A;
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
International journal of hematology 2000;72(3):285-9.
2000: Lengfelder E; Reichert A; Schoch C; Haase D; Haferlach T; Löffler H; Staib P; Heyll A; Seifarth W; Saussele S; Fonatsch C; Gassmann W; Ludwig W D; Hochhaus A; Beelen D; Aul C; Sauerland M C; Heinecke A; Hehlmann R; Wörmann B; Hiddemann W; Büchner T
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(8):1362-70.
2000: Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
British journal of haematology 2000;110(1):170-9.
2000: Wuchter C; Harbott J; Schoch C; Schnittger S; Borkhardt A; Karawajew L; Ratei R; Ruppert V; Haferlach T; Creutzig U; Dörken B; Ludwig W D
Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(7):1232-8.
2000: Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig W D
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Haematologica 2000;85(7):711-21.
2000: Schnittger S; Kinkelin U; Schoch C; Heinecke A; Haase D; Haferlach T; Büchner T; Wörmann B; Hiddemann W; Griesinger F
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(5):796-804.
1999: Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig W D
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(12):1943-53.
1999: Gahn B; Wendenburg B; Troff C; Neef J; Grove D; Haferlach T; Hiddemann W; Wörmann B
Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level.
British journal of haematology 1999;105(4):955-9.
1999: Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig W D; Sauerland M C; Heinecke A
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Blood 1999;93(12):4116-24.
1998: Haferlach T; Löffler H; Nickenig C; Ramm-Petersen L; Meeder M; Schoch R; Schlegelberger B; Schnittger S; Schoch C; Hiddemann W
Cell lineage specific involvement in acute promyelocytic leukaemia (APL) using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques for the detection of the translocation t(15;17)(q22;q12).
British journal of haematology 1998;103(1):93-9.
1997: Glasmacher A; Haferlach T; Gorschlüter M; Mezger J; Maintz C; Clemens M R; Ko Y; Hahn C; Ubelacker R; Kleinschmidt R; Gieseler F
Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 5():S22-6.
1997: Haferlach T; Löffler H
Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 5():S5-9.
1997: Schoch C; Haase D; Fonatsch C; Haferlach T; Löffler H; Schlegelberger B; Hossfeld D K; Becher R; Sauerland M C; Heinecke A; Wörmann B; Büchner T; Hiddemann W
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
British journal of haematology 1997;99(3):605-11.
1997: Haferlach T; Winkemann M; Ramm-Petersen L; Meeder M; Schoch R; Weber-Matthiesen K; Schlegelberger B; Schoch C; Ludwig W D; Hiddemann W; Löffler H
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level.
British journal of haematology 1997;99(2):452-9.
1997: Haferlach T; Hiddemann W
[Liver involvement in hematologic diseases]
Der Internist 1997;38(10):977-83.
1997: Gassmann W; Löffler H; Thiel E; Ludwig W D; Schwartz S; Haferlach T; Maurer J; Rieder H; Fonatsch C; Gökbuget N; Hoelzer D
Morphological and cytochemical findings in 150 cases of T-lineage acute lymphoblastic leukaemia in adults. German Multicentre ALL Study Group (GMALL).
British journal of haematology 1997;97(2):372-82.
1997: Haferlach T; Winkemann M; Nickenig C; Meeder M; Ramm-Petersen L; Schoch R; Nickelsen M; Weber-Matthiesen K; Schlegelberger B; Schoch C; Gassmann W; Loffler H
Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques.
British journal of haematology 1997;97(1):99-106.
1996: Haferlach T; Bennett J M; Löffler H; Gassmann W; Andersen J W; Tuzuner N; Casslleth P A; Fonatsch C; Schoch C; Schlegelberger B; Becher R; Thiel E; Ludwig W D; Sauerland M C; Heinecke A; Büchner T
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.
Leukemia & lymphoma 1996;23(3-4):227-34.
1996: Schoch C; Haase D; Haferlach T; Freund M; Link H; Lengfelder E; Löffler H; Büchner T; Fonatsch C
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients.
British journal of haematology 1996;94(3):493-500.
1996: Schoch C; Haase D; Haferlach T; Gudat H; Büchner T; Freund M; Link H; Lengfelder E; Wandt H; Sauerland M C; Löffler H; Fonatsch C
Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(8):1288-95.
1996: Haferlach T
More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10 Suppl 3():S5-S9.
1996: Haferlach T; Winkemann M; Löffler H; Schoch R; Gassmann W; Fonatsch C; Schoch C; Poetsch M; Weber-Matthiesen K; Schlegelberger B
The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization.
Blood 1996;87(6):2459-63.
1996: Zhang Y; Poetsch M; Weber-Matthiesen K; Rohde K; Winkemann M; Haferlach T; Gassmann W; Ludwig W D; Grote W; Löffler H; Schlegelberger B
Secondary acute leukaemias with 11q23 rearrangement: clinical, cytogenetic, FISH and FICTION studies.
British journal of haematology 1996;92(3):673-80.
1996: Wichmann M G; Haferlach T; Suttorp M; Zhang Y; Neppert J
Can blood group O red cells of donor origin acquire weak group A reactivity through serum A transferase of the recipient after bone marrow transplantation?
Infusionstherapie und Transfusionsmedizin 1996;23(1):29-31.
1996: Schlegelberger B; Zwingers T; Hohenadel K; Henne-Bruns D; Schmitz N; Haferlach T; Tirier C; Bartels H; Sonnen R; Kuse R
Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):593-9.
1996: Schoch R; Jenisch S; Haferlach T; Müller-Ruchholtz W; Gassmann W; Löffler H
Glass slide smears are a suitable source for RT-PCR-based analysis of chromosomal aberrations in leukaemias.
British journal of haematology 1996;92(1):140-2.
1996: Hauschild A; Haferlach T; Löffler H; Christophers E
Multiple myeloma first presenting as cutaneous plasmacytoma.
Journal of the American Academy of Dermatology 1996;34(1):146-8.
1995: Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Blood 1995;86(10):3970-8.
1995: Schmitz N; Dreger P; Suttorp M; Rohwedder E B; Haferlach T; Löffler H; Hunter A; Russell N H
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
Blood 1995;85(6):1666-72.
1995: Löffler H; Gassmann W; Haferlach T
AML M1 and M2 with eosinophilia and AML M4Eo: diagnostic and clinical aspects.
Leukemia & lymphoma 1995;18 Suppl 1():61-3.
1994: Dreger P; Haferlach T; Eckstein V; Jacobs S; Suttorp M; Löffler H; Müller-Ruchholtz W; Schmitz N
G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.
British journal of haematology 1994;87(3):609-13.
1994: Wichmann M G; Haferlach T; Suttorp M; Zhang Y; Neppert J
Can blood group O red cells of donor origin acquire weak group A reactivity through serum A transferase of the recipient after bone marrow transplantation?
Beiträge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine 1994;32():146-8.
1993: Dreger P; Marquardt P; Haferlach T; Jacobs S; Mülverstedt T; Eckstein V; Suttorp M; Löffler H; Müller-Ruchholtz W; Schmitz N
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
British journal of cancer 1993;68(5):950-7.
1993: Haferlach T; Löffler H; Glass B; Gassmann W
Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse.
The Clinical investigator 1993;71(10):774-9.
1993: Schmitz N; Glass B; Dreger P; Haferlach T; Horst H A; Ollech-Chwoyka J; Suttorp M; Gassmann W; Löffler H
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Annals of hematology 1993;66(5):251-6.
1993: Haferlach T; Gassmann W; Löffler H; Jürgensen C; Noak J; Ludwig W D; Thiel E; Haase D; Fonatsch C; Becher R
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.
Annals of hematology 1993;66(4):165-70.
1993: Dreger P; Suttorp M; Haferlach T; Löffler H; Schmitz N; Schroyens W
Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation.
Blood 1993;81(5):1404-7.
1991: Schmitz N; Prange E; Haferlach T; Griesser H; Sonnen R; Schlegelberger B; Claus S; Löffler H
High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).
Bone marrow transplantation 1991;8(6):503-6.
1991: von Wussow P; Pralle H; Hochkeppel H K; Jakschies D; Sonnen S; Schmidt H; Müller-Rosenau D; Franke M; Haferlach T; Zwingers T
Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia.
Blood 1991;78(1):38-43.
1986: Löffler H; Gassmann W; Haferlach T; Pralle H
[A comparison of staging classifications of plasmacytoma]
Onkologie 1986;9(4):196, 199-201.
1985: Gassmann W; Pralle H; Haferlach T; Pandurevic S; Graubner M; Schmitz N; Löffler H
Staging systems for multiple myeloma: a comparison.
British journal of haematology 1985;59(4):703-11.

Sign-in to see more